Differential effects of physostigmine and 1,2,3,4-tetrahydro-9-aminoacridine on the beta-adrenoceptor transduction system.

[1]  M. Dierssen,et al.  Post-train administration of 9-amino-1,2,3,4-tetrahydroacridine enhances passive avoidance retention and decreases β-adrenoceptor-linked cyclic AMP formation in middle-aged rats , 1992, Brain Research.

[2]  M. Dierssen,et al.  EFFECT OF 9-AMINO-1, 2, 3, 4-TETRAHYDROACRIDINE ON PASSIVE AVOIDANCE RETENTION AND SS-ADRENOCEPTOR LINKED CYCLIC AMP ACCUMULATION IN MIDDLE AGED RATS , 1992 .

[3]  S. E. Freeman,et al.  Tacrine: A pharmacological review , 1991, Progress in Neurobiology.

[4]  M. Dierssen,et al.  Acute effects of tetrahydroaminoacridine on β-adrenoceptor-linked cyclic AMP accumulation in brain of young and middle-aged rats , 1991, Neuroscience Letters.

[5]  I. Williams,et al.  Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. , 1989, European journal of pharmacology.

[6]  J. Moossy,et al.  A brain regional analysis of morphologic and cholinergic abnormalities in Alzheimer's disease. , 1989, Archives of neurology.

[7]  B. Weiss.  Modulation of Adrenergic Receptors During Aging , 1988, Neurobiology of Aging.

[8]  I. Abrass,et al.  Alpha- and beta-adrenergic receptor function in the brain during senescence , 1988, Neurobiology of Aging.

[9]  I. Abrass,et al.  Decreased beta-adrenergic agonist affinity and adenylate cyclase activity in senescent rat lung. , 1983, Journal of gerontology.

[10]  J. Whelan,et al.  A simple direct assay for cyclic AMP in plasma and other biological samples using an improved competitive protein binding technique. , 1974, Clinica chimica acta; international journal of clinical chemistry.

[11]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[12]  F. Forette,et al.  Alzheimer's disease and THA: a review of the cholinergic theory and of preliminary results. , 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[13]  J. C. Stoof,et al.  Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease. , 1988, Life sciences.

[14]  J. Patočka,et al.  In vivo kinetics of blood cholinesterase inhibition by 9-amino-1, 2, 3, 4-tetrahydroacridine, its 7-methoxy derivative and physostigmine in rats. , 1979, Physiologia Bohemoslovaca.